Poolbeg Pharma lands deal with AI firm to pinpoint effective virus drugs

US giant OneThree Biotech will lend Open Orphan spinout its state-of-the-art technology to accelerate treatment of severe respiratory infection RSV

Professor Luke O'Neill, non-executive director at Poolbeg Pharma: says one of the few benefits of the Covid-19 pandemic was that it had shown the pharmaceutical industry that it could conduct clinical trials far more effectively and rapidly than before. Picture: Fergal Phillips